Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Drugs & Aging|July 30, 2020
Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-WetSender Herschorn, David Staskin, Carol R Schermer, et al.Journal of the American Society of Hypertension : JASH|September 6, 2018
Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndromeWilliam B White, Emad Siddiqui, Tri Tat, et al.The Journal of Trauma|April 23, 2003
Trauma patient willingness to participate in alcohol screening and interventionCarol R Schermer, Lori A Bloomfield, Stephen W Lu, et al.The Journal of Trauma|February 4, 2006
Trauma center brief interventions for alcohol disorders decrease subsequent driving under the influence arrestsCarol R Schermer, Theresa B Moyers, William R Miller, et al.International Urogynecology Journal|June 17, 2017
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)David Staskin, Sender Herschorn, Jonathan Fialkov, et al.European Urology|November 18, 2019
Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)Adrian Wagg, David Staskin, Eli Engel, et al.The Journal of Trauma and Acute Care Surgery|January 25, 2014
Enteral albuterol decreases the need for chronotropic agents in patients with cervical spinal cord injury-induced bradycardiaCharity H Evans, Jeremiah J Duby, Andrew J Berry, et al.Journal of Emergencies, Trauma, and Shock|March 16, 2013
Pre-hospital transport times and survival for Hypotensive patients with penetrating thoracic traumaMamta Swaroop, David C Straus, Ogo Agubuzu, et al.Neurourology and Urodynamics|April 4, 2017
A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instrumentsSuvapun Bunniran, Cralen Davis, Rita Kristy, et al.Health and Quality of Life Outcomes|April 21, 2018
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)Sender Herschorn, David Staskin, Le Mai Tu, et al.Pageof 5